L. McGregor

发表

Inherited germline TP53 mutation encodes a protein with an aberrant C-terminal motif in a case of pediatric adrenocortical tumor

S. Shurtleff, R. Ribeiro, R. Kriwacki, 2010, Familial Cancer.

Phase I and Clinical Pharmacology Study of Bevacizumab, Sorafenib, and Low-Dose Cyclophosphamide in Children and Young Adults with Refractory/Recurrent Solid Tumors

W. Reddick, J. Panetta, S. Spunt, 2012, Clinical Cancer Research.

Interested in publishing with us ? Contact book

L. McGregor, Neema Bhat, 2018 .

Neuroblastoma: The Clinical Aspects

L. McGregor, Neema Bhat, 2017 .

Significance of pleural effusion in neuroblastoma

A. Davidoff, L. McGregor, J. Khoury, 2007, Pediatric blood & cancer.

A single-arm pilot phase II study of gefitinib and irinotecan in children with newly diagnosed high-risk neuroblastoma

P. Houghton, A. Davidoff, L. McGregor, 2012, Investigational New Drugs.

UGT1A1 promoter genotype correlates with SN-38 pharmacokinetics, but not severe toxicity in patients receiving low-dose irinotecan.

J. Panetta, C. Rodríguez-Galindo, L. McGregor, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Margin status and tumor recurrence after nephron-sparing surgery for bilateral Wilms tumor.

M. Williams, A. Davidoff, L. McGregor, 2013, Journal of pediatric surgery.

Attendance at National Cancer Institute and Children's Oncology Group Facilities for Children, Adolescents, and Young Adults with Cancer in Pennsylvania: A Population-Based Study.

L. McGregor, E. Lengerich, J. Drabick, 2020, Journal of adolescent and young adult oncology.

Isolated subcutaneous metastasis of osteosarcoma 5 years after initial diagnosis.

A. Bahrami, J. Sandoval, A. Davidoff, 2011, Journal of pediatric surgery.

Phase I Clinical Trial of Ifosfamide, Oxaliplatin, and Etoposide (IOE) in Pediatric Patients With Refractory Solid Tumors

S. Spunt, L. McGregor, W. Furman, 2015, Journal of pediatric hematology/oncology.

Phase 1 study of oxaliplatin and irinotecan in pediatric patients with refractory solid tumors

P. Adamson, S. Spunt, L. McGregor, 2009, Cancer.

A phase 1 trial of everolimus and bevacizumab in children with recurrent solid tumors

L. McGregor, W. Furman, C. Stewart, 2020, Cancer.

Phase I trial of a novel anti-GD2 monoclonal antibody, Hu14.18K322A, designed to decrease toxicity in children with refractory or recurrent neuroblastoma.

KyungMann Kim, L. McGregor, J. Allay, 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Dose escalation of intravenous irinotecan using oral cefpodoxime: A phase I study in pediatric patients with refractory solid tumors

P. Houghton, C. Rodríguez-Galindo, L. McGregor, 2012, Pediatric blood & cancer.

Tyrosine kinase inhibitor enhances the bioavailability of oral irinotecan in pediatric patients with refractory solid tumors.

P. Houghton, J. Panetta, S. Spunt, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

FOLLICLE-DERIVED THYROID CANCER IN YOUNG PEOPLE: The Duke Experience

L. McGregor, P. Rosoff, 2001, Pediatric hematology and oncology.

Repeat nephron-sparing surgery for children with bilateral Wilms tumor.

A. Davidoff, L. McGregor, J. Dome, 2014, Journal of pediatric surgery.

Locoregional tumor progression after radiation therapy influences overall survival in pediatric patients with neuroblastoma.

T. Merchant, L. McGregor, M. Krasin, 2007, International journal of radiation oncology, biology, physics.

A novel anti-GD2 monoclonal antibody (mAb), hu14.18K322A, in children with refractory or recurrent neuroblastoma: Early-phase evaluation.

L. McGregor, W. Furman, R. Handgretinger, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Pediatric cancers in the new millennium: dramatic progress, new challenges.

L. McGregor, M. Metzger, V. Santana, 2007, Oncology.

Establishment and Characterization of the First Pediatric Adrenocortical Carcinoma Xenograft Model Identifies Topotecan as a Potential Chemotherapeutic Agent

R. Ribeiro, C. Morton, A. Davidoff, 2013, Clinical Cancer Research.

Phase I dose escalation and pharmacokinetic study of oral gefitinib and irinotecan in children with refractory solid tumors

L. McGregor, R. Brennan, W. Furman, 2014, Cancer Chemotherapy and Pharmacology.

Avoiding misdiagnosing neuroblastoma as Wilms tumor.

A. Davidoff, L. McGregor, W. Furman, 2008, Journal of pediatric surgery.

Zygomycosis originating from an odontogenic infection in a pediatric oncology patient.

L. McGregor, E. Adderson, V. Santana, 2010, Diagnostic microbiology and infectious disease.

Subsequent Malignant Neoplasms in Pediatric Patients Initially Diagnosed With Neuroblastoma

Sara M. Federico, M. Hudson, S. Spunt, 2015, Journal of pediatric hematology/oncology.

Radiation therapy as part of local control of metastatic neuroblastoma: the St Jude Children's Research Hospital experience.

A. Davidoff, L. McGregor, W. Furman, 2010, Journal of pediatric surgery.

Disease control intervals in high‐risk neuroblastoma

L. McGregor, W. Furman, C. Billups, 2008, Cancer.

Phase 1 study of an oxaliplatin and etoposide regimen in pediatric patients with recurrent solid tumors

S. Spunt, L. McGregor, W. Furman, 2009, Cancer.

Epidermal growth factor receptor polymorphisms and risk for toxicity in paediatric patients treated with gefitinib.

L. McGregor, N. Daw, W. Furman, 2010, European journal of cancer.

The impact of early resection of primary neuroblastoma on the survival of children older than 1 year of age with stage 4 disease

A. Davidoff, C. Fuller, L. McGregor, 2005, Cancer.

Intensity modulated radiation therapy provides excellent local control in high‐risk abdominal neuroblastoma

A. Davidoff, L. McGregor, W. Furman, 2013, Pediatric blood & cancer.

K-ras and p53 in pancreatic cancer: association with medical history, histopathology, and environmental exposures in a population-based study.

Jack A. Taylor, J. Brock, E. Holly, 2000, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

Cancer Therapy : Preclinical Establishment and Characterization of the First Pediatric Adrenocortical Carcinoma Xenograft Model Identi fi es Topotecan as a Potential Chemotherapeutic Agent

R. Ribeiro, C. Morton, A. Davidoff, 2013 .

A novel EWSR1‐CREB3L1 fusion transcript in a case of small cell osteosarcoma

S. Raimondi, H. Dorfman, L. McGregor, 2011, Genes, chromosomes & cancer.

Jaw dysfunction related to pterygoid and masseter muscle dosimetry after radiation therapy in children and young adults with head-and-neck sarcomas.

T. Merchant, S. Spunt, A. Davidoff, 2012, International journal of radiation oncology, biology, physics.

PAPILLARY ADENOCARCINOMA OF THE THYROID IN A THYROGLOSSAL DUCT CYST

L. McGregor, P. Rosoff, 2000, Pediatric hematology and oncology.

A phase I study of ifosfamide, oxaliplatin, and etoposide (IOE) in pediatric patients with refractory solid tumors.

S. Spunt, L. McGregor, W. Furman, 2011, Journal of Clinical Oncology.

UGT1A1 promoter genotype correlates with pharmacokinetics but not toxicity in patients receiving protracted irinotecan (IRN).

J. Panetta, L. McGregor, W. Furman, 2006, Journal of Clinical Oncology.

Rapamycin increases neuroblastoma xenograft and host stromal derived osteoprotegerin inhibiting osteolytic bone disease in a bone metastasis model.

A. Davidoff, L. McGregor, W. Furman, 2013, Journal of pediatric surgery.

Dose escalation of intravenous irinotecan using oral cefpodoxime: A phase I study in pediatric patients with refractory solid tumors

P. Houghton, C. Rodríguez-Galindo, L. McGregor, 2012, Pediatric blood & cancer.

Phase I Clinical Trial of Ifosfamide, Oxaliplatin, and Etoposide (IOE) in Pediatric Patients With Refractory Solid Tumors

S. Spunt, L. McGregor, W. Furman, 2015, Journal of pediatric hematology/oncology.